Literature DB >> 6995131

Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.

U Abshagen, S Spörl-Radun, J Marinow.   

Abstract

The steady-state kinetics of chlorophenoxyisobuytric acid (CPIB) and of bezafibrate were investigated in a strictly controlled, randomised cross-over study in 10 female volunteers, after the conventional oral doses of clofibrate 0.5 g and bezafibrate f0.2 g at 8-h intervals. The mean steady-state concentration of CPIB in serum was 34 times higher than that of bezafibrate, which was due to the considerable cumulation of CPIB, whereas no cumulation of bezafibrate was observed. This is supported by comparison of the AUCs, and of the maximum and mean concentrations of bezafibrate after the first and last doses. beta (0.44 and 0.49 h(-1)) and the half-lives (1.6 and 1.4h) were almost identical after the first and last doses of bezafibrate. The median total clearances of CPIB and bezafibrate amounted to 10.5 and 142.5ml/min, respectively, if complete absorption of both drugs is assumed. Since the apparent volumes of distribution were in the same range for both drugs, the amount of drug present in the organism in steady-state also differed by a factor of approximately 30 under the usual dosage regimen.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6995131     DOI: 10.1007/bf00625805

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.

Authors:  P T Männistö; J Tuomisto; A Jounela; O Penttilä
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975-04

2.  A rapid gas chromatographic method for the determination of chlorophenoxyisobutyric acid in plasma and urine.

Authors:  R Gugler; C Jensen
Journal:  J Chromatogr       Date:  1976-02-04

3.  Lack of effect of cholestyramine on the pharmacokinetics of clofibrate in man.

Authors:  A Sedaghat; E H Ahrens
Journal:  Eur J Clin Invest       Date:  1975-04       Impact factor: 4.686

4.  Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.

Authors:  A G Olsson; S Rössner; G Walldius; L A Carlson; P D Lang
Journal:  Atherosclerosis       Date:  1977-07       Impact factor: 5.162

5.  A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

Authors: 
Journal:  Br Heart J       Date:  1978-10

Review 6.  Clinical pharmacokinetics of hypolipidaemic drugs.

Authors:  R Gugler
Journal:  Clin Pharmacokinet       Date:  1978 Nov-Dec       Impact factor: 6.447

7.  [Biochemical principles, therapeutic significance and prevention of drug interactions on the pharmacokinetic level].

Authors:  H Remmer
Journal:  Internist (Berl)       Date:  1979-05       Impact factor: 0.743

8.  Disposition pharmacokinetics of bezafibrate in man.

Authors:  U Abshagen; W Bablok; K Koch; P D Lang; H A Schmidt; M Senn; H Stork
Journal:  Eur J Clin Pharmacol       Date:  1979-08       Impact factor: 2.953

9.  [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].

Authors:  K Bolzano; F Krempler; B Schellenberg; G Schlierf
Journal:  Acta Med Austriaca       Date:  1979

10.  Clofibrate kinetics after single and multiple doses.

Authors:  R Gugler; J Hartlapp
Journal:  Clin Pharmacol Ther       Date:  1978-10       Impact factor: 6.875

View more
  10 in total

1.  Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial.

Authors:  Mette Cathrine Ørngreen; Karen Lindhardt Madsen; Nicolai Preisler; Grete Andersen; John Vissing; Pascal Laforêt
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

2.  Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients.

Authors:  G Neugebauer; D Platt; T Vömel; W Lösch
Journal:  Klin Wochenschr       Date:  1988-03-15

3.  Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.

Authors:  U Abshagen; W Kösters; B Kaufmann; P D Lang
Journal:  Klin Wochenschr       Date:  1980-09-01

Review 4.  Treatment Opportunities in Patients With Metabolic Myopathies.

Authors:  Mette Cathrine Ørngreen; John Vissing
Journal:  Curr Treat Options Neurol       Date:  2017-09-21       Impact factor: 3.598

Review 5.  Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

Authors:  K L Goa; L B Barradell; G L Plosker
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 6.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

7.  Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: pharmacokinetics and effects.

Authors:  P Grützmacher; E H Scheuermann; W Siede; P D Lang; U Abshagen; H W Radtke; C A Baldamus; W Schoeppe
Journal:  Klin Wochenschr       Date:  1986-10-01

Review 8.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

9.  Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.

Authors:  P Anderson; H E Norbeck
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

Review 10.  PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders.

Authors:  F Djouadi; J Bastin
Journal:  J Inherit Metab Dis       Date:  2008-04-04       Impact factor: 4.982

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.